Skip to main content
Clinical Trials/NCT03144401
NCT03144401
Completed
Phase 2

Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section: A Double-blind Randomized Clinical Trial

Ain Shams University1 site in 1 country240 target enrollmentApril 10, 2017

Overview

Phase
Phase 2
Intervention
Misoprostol
Conditions
Cesarean Section
Sponsor
Ain Shams University
Enrollment
240
Locations
1
Primary Endpoint
Need for extra uterotonics
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This prospective double-blind placebo-controlled randomized clinical trial will be conducted at Ain-Shams University Maternity Hospital from April 2017 till October 2017. 120 women candidate foe elective cesarean section will receive preoperative sublingual 400 microgram of misoprostol, and another 120 women will receive postoperative sublingual 400 microgram of misoprostol.

Registry
clinicaltrials.gov
Start Date
April 10, 2017
End Date
February 1, 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamed S Sweed, MD

Assistant Professor

Ain Shams University

Eligibility Criteria

Inclusion Criteria

  • Patients booked for elective cesarean section.
  • Singleton pregnancies.
  • Full term pregnancies (GA 37- 42 Wks).
  • Age (18-40 yrs).
  • body mass index (BMI) (20-30(Kg/m2 .

Exclusion Criteria

  • Contraindication to spinal anesthesia.
  • Blood dyscrasias.
  • Large fibroids.
  • Multiple pregnancies.
  • Overdistended uterus eg. Hydramnios.
  • Pre-eclampsia.
  • Marked maternal anemia (Preoperative hemoglobin \< 9 gm/dl).
  • Previous history of PPH.
  • Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol.
  • Placenta previa.

Arms & Interventions

Preoperative

• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) "2 tablets" and postoperative sublingual placebo"2 tablets".

Intervention: Misoprostol

Preoperative

• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) "2 tablets" and postoperative sublingual placebo"2 tablets".

Intervention: Placebo

Postoperative

• Group no.2 will receive preoperative sublingual placebo "2 tablets" and postoperative sublingual 400 microgram of misoprostol (Sigma) " 2 tablets" .

Intervention: Misoprostol

Postoperative

• Group no.2 will receive preoperative sublingual placebo "2 tablets" and postoperative sublingual 400 microgram of misoprostol (Sigma) " 2 tablets" .

Intervention: Placebo

Outcomes

Primary Outcomes

Need for extra uterotonics

Time Frame: 24 hours

Secondary Outcomes

  • postpartum hemorrhage(24 hours)
  • intraoperative blood loss(intraoperative)
  • neonatal outcome(5 minutes)

Study Sites (1)

Loading locations...

Similar Trials